SCHEMBL8745758

SCHEMBL8745758

Cc1cc2ccc(C#N)nc2cc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NQO1 P15559 1/20 0.50
KMT2A Q03164 3/20 0.44
POLB P06746 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
HPGDS O60760 1/20 0.36
KDM4E B2RXH2 2/20 0.36
MEN1 O00255 2/20 0.36
MAPT P10636 2/20 0.36
PABPC1 P11940 1/20 0.36
ALDH1A1 P00352 2/20 0.35
USP2 O75604 1/20 0.35
LMNA P02545 1/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TTR P02766 1/20 0.35
EGLN2 Q96KS0 1/20 0.35
SOS2 Q07890 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5020257 0.85 NQO1 (0.51) NQO1KMT2AHPGDSKDM4EMEN1
SCHEMBL15889957 0.77 NQO1 (0.59) NQO1KMT2APOLBL3MBTL1TSHR
SCHEMBL9186322 0.76 CYP1A2 (0.52) POLBKDM4EMAPTLMNA
SCHEMBL5020160 0.76 NOTUM (0.44) NQO1L3MBTL1KDM4EALDH1A1TDP1
SCHEMBL15876559 0.76 NQO1 (0.58) NQO1KMT2AL3MBTL1HPGDSKDM4E
SCHEMBL756229 0.74 CYP1A2 (0.55) NQO1KMT2AL3MBTL1ALOX15TSHR
SCHEMBL743391 0.73 NQO1 (0.59) NQO1HPGDSKDM4ESOS2PSMB8
SCHEMBL8002770 0.73 NQO1 (0.64) NQO1KMT2AL3MBTL1ALOX15TSHR
SCHEMBL14629283 0.71 NQO1 (0.56) NQO1KMT2APOLBHPGDSKDM4E
SCHEMBL21880293 0.70 NQO1 (0.60) NQO1KMT2APOLBL3MBTL1HPGDS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180221364-A1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS, INC. 2018-08-09 US disclosed
US-20170143694-A1 METALLOENZYME INHIBITOR COMPOUNDS INNOCRIN PHARMACEUTICALS, INC. 2017-05-25 US disclosed
US-20140121248-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2014-05-01 US disclosed
US-8623892-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2014-01-07 US disclosed
US-20130184309-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2013-07-18 US disclosed
US-8389543-B2 Metalloenzyme inhibitor compounds VIAMET PHARMACEUTICALS, INC. (US) 2013-03-05 US disclosed
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121248-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NQO1 44/4885KMT2A 1886/4885POLB 1777/4885
US-20180221364-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NQO1 44/4885KMT2A 1886/4885POLB 1777/4885
US-20130184309-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NQO1 44/4885KMT2A 1886/4885POLB 1777/4885
US-20170143694-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NQO1 44/4885KMT2A 1886/4885POLB 1777/4885
US-20120129886-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO NQO1 44/4885KMT2A 1886/4885POLB 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.